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Introduction 
Bromocriptine is a dopamine agonist frequently used to 
treat Parkinson’s disease, either in association with, or as 
an alternative to, classical dopamine agonists. The main 
side-effects of bromocriptine are fairly well recognized. 
Although the association of pleuropulmonary disorders 
has not been convincingly proved, accumulating evidence 
suggests a cause-and-effect relationship. Pleuropulmonary 
involvement can present as pleural thickening, pleural 
effusion and interstitial shadowings. 
We report a patient who developed pleuropulmonary 
disease after long-term use of bromocriptine (1,2). 
Case Report 
A 63-year-old Caucasian non-smoking female with a past 
clinical history of hypertension, colon diverticulosis and no 
relevant occupational history, was diagnosed as having 
Parkinson’s disease in 1988. After temporary treatment 
with L-Dopa, in 1990 the therapy was changed to bromo- 
criptine. In July 1994 the patient was referred to our 
Received 23 No\iember 1996 and accepted in revised form 13 
February 1998. 
Correspondence should be addressed to: C. Domingo, S. 
Pneumologia-planta l”, Consorci Hospitalari de1 Part Tauli, Part 
Tauli s/n, 08 208 Sabadell, Barcelona, Spain. 
hospital for a 6 months’ history of progressive dyspnoea, 
anorexia and a weight of lost of 10 kg. Physical examina- 
tion disclosed only the presence of crackles at both lung 
bases. Blood analysis: Erythrocyte sedimentation rate 
(ESR), 106; leukocyte count, haemoglobin and biochemis- 
try data were normal; LDH 356 U l- ‘; proteins 81 g l- ‘; 
Latex and Waler-Rose, Carcino-embrionary antigen, 
Alpha-fetoprotein and a screening of auto-antibodies were 
negative. C-reactive protein (CRP): 9.26. Angiotensin con- 
verting enzyme value was within normal limits. Arterial 
blood gases breathing room air: PaO, 83; PaCO, 40; 
pH 7.44. PPD test was negative. Chest X-ray showed a 
bilateral pleural effusion and bilateral interstitial shadow- 
ings [Plate l(a)]. A thoracocentesis disclosed the presence of 
a sero-hematic pleural effusion with: 390 red blood cells 
mmp3; 10 leukocytes mm - 3; proteins 25 g 1 - i; LDH 
125 U I- ‘; ADA 3.7 U 1~ ‘. The cytological examination 
and the Lowenstein culture was negative. Bronchoscopy 
was normal. The bronchoalveolar lavage showed: 740 cells 
mmp3; macrophages 8 1%; lymphocytes 1%; polymorpho- 
nuclears, 1%; no malignant cells or asbestos fibres were 
observed in the bronchoaspirate. A pleural biopsy was 
performed revealing the presence of chronic fibrinous 
pleuritis. A thoracic computed tomography (CT) scan evi- 
denced a bilateral pleural effusion and fibrotic and ground 
glass images in both lower lungs. Forced spirometry: FEV, 
1.120 1 (60%); FVC 1.3201 (52%); FEV,/FVC 85%. 
RV 1.231 1 (71%); TLC 2.98 1 (68%). Co-transfer was nor- 
mal. During the patient’s in-hospital stay, bromocriptine 
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PLATE 1. (a) Bilateral pleural effusion and bilateral interstitial shadowings were observed. (b) On recovering, bilateral 
pleural thickening with mild bilateral pleural shadowings were still present. 
treatment was stopped and L-Dopa was re-started. The 
clinical follow-up showed a progressive improvement of the 
dyspnoea and the toxic syndrome. Thirty-two months later; 
blood analysis showed a progressive decrease of ESR and 
CRP (the values were 37 and 0.34, respectively) and chest 
X-ray showed a bilateral pleural thickening with mild 
bilateral pleural shadowings. A CT scan confirmed the 
presence of the pleural thickening and allowed the detection 
of the presence of a minimum amount of pleural effusion in 
the right hemithorax and fibrotic images in both lower 
lungs [Plate l(b)]. 
Discussion 
Several drugs have been considered responsible for pulmon- 
ary toxicity, although potentially severe pleuropulmonary 
disease due to drug side-effects is relatively infrequent. The 
drugs considered potentially responsible for both lung 
and pleural toxicity include nitrofurantoin, practolol, 
methysergide, ergotamine and dopamine-agonists (3,4). 
Since the introduction of dopamine-agonists several 
authors have communicated the association between 
pleuropulmonary disease and dopamine-agonist admin- 
istration. This side-effect has been observed with the use of 
bromocriptine as well as with new drugs such as cabergoline 
and lisuride (5,6). 
The incidence of this side-effect ranges between 2% and 
5% (3) and the appearance of the clinical symptoms ranges 
between 5 months and 4 years (7). The population most 
usually affected are men over 60 years with a history of 
long-term cigarette smoking. The main relevant symptoms 
include dyspnoea, followed by pleuritic chest pain and/or 
dry cough. Chest X-ray shows unilateral or bilateral pleural 
effusion with or without pulmonary infiltrates (3). The 
pleural effusion is usually an exudate rich in lymphocytes 
and eosinophils (3,7). Constrictive pericarditis has also been 
observed (8). 
The pathophysiological route of this side-effect remains 
unknown, but it has been suggested that a serotonin- 
induced effect could at least partially contribute to the 
development of the disease, since this is the pharmacologi- 
cal mechanism of other drugs such as ergotamine and 
methysergide, ergot alkaloid derivatives that have been 
associated with the development of petroperitoneal and 
lung fibrosis (3). 
The natural history of pleuropulmonary disease after 
drug withdrawal is also unclear; the majority of patients 
gradually improve although complete clinical, radiological 
and biological recovery does not always occur (4). Thus, it 
is not infrequent to observe the presence of elevated values 
of ESR and CRP as well as residual pleural thickening in 
the chest X-ray, as happened in our case. Our case differs 
from most other published cases in that the patient was a 
non-smoking woman, and the pleural effusion was a trasu- 
date instead of an exudate (since only one thoracocentesis 
was performed, we can not rule out that the presence of 
erythrocytes was an artefact). 
Although a cause-and-effect relationship has not been 
confirmed, several authors (3,7) consider there is convincing 
evidence of a causative link between bromocriptine therapy 
and pleuropulmonary disease. Moreover. our case meets 
four of the five criteria established by Karch and Lasagna 
(9). The fifth criterion could not be confirmed, since we 
considered it unethical to re-start treatment with bromo- 
criptine after clinical improvement. 
Finally, we agree with the authors who recommend chest 
X-ray and pulmonary function evaluation prior to treat- 
ment with bromocriptine, with follow-up studies if the 
patient develops respiratory symptoms. Physicians prescrib- 
ing bromocriptine should be aware of this unusual side- 
effect so as to ensure early recognition and prompt 
withdrawal of the therapy, although in some cases the 
treatment was continued without progression of the disease 
~3). 
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This is the first case of an adult who developed recurrent pulmonary edema as a result of unrecognized chronic upper 
airway obstruction due to polyarticular juvenile rheumatoid arthritis. The case highlights the importance of 
considering upper airway involvement in the differential diagnosis of sedentary patients with arthritic joint disease 
and breathing difficulties. 
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Introduction 
Pulmonary edema as the result of acute upper airway 
obstruction has been described repeatedly in children and 
adults (1,2). Pulmonary edema as the result of chronic 
upper airway obstruction has been reported, however, 
mostly in children since its first description in 1966 (3). An 
extensive literature search found only three case reports of 
pulmonary edema as the result of chronic upper airway 
obstruction in adults. In two cases the patients had severe 
obstructive sleep apnea (4) while the third patient had 
malignant tracheal obstruction (5). This is the first case 
of an adult who unknowingly developed chronic upper air- 
way obstruction due to polyarticular juvenile rheumatoid 
arthritis and as a result recurrent episodes of pulmonary 
edema. 
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Case Report 
A 64-year-old man with longstanding polyarticular juvenile 
rheumatoid arthritis was admitted for lower extremity 
cellulitis. Blood pressure was 120/60 mmHg, heart rate 122 
beats min - I, respiratory rate 24 min - ‘, and temperature 
38.3”C. Physical examination revealed mild wheezing over 
the right hung, a displaced point of maximum impulse, a 316 
systolic murmur over the precordium, and scoliosis of the 
thoracic spine. The chest roentgenogram was unremark- 
able except for cardiomegaly and kyphoscoliosis (Plate 1). 
Medications included indomethacin and theophylline. Past 
medical history included aortic valvular sclerosis with 
normal left ventricular function, allergy to penicillin, 
multiple joint replacements, iridocyclitis, and glaucoma; in 
addition the patient had been told that he had bronchial 
asthma after an emergency room visit for shortness of 
breath 5 years prior to admission. 
The patient was started on vancomycin. On day 4 the 
patient developed severe respiratory distress with rhonchi 
over both lungs and was placed on 100% oxygen and given 
